论文部分内容阅读
目的探讨长期口服拉米夫定对慢性乙型肝炎患者进展发病原发肝癌影响。方法回顾分析了2005年7月至2008年7月共诊治慢性乙型肝炎(CHB)患者620例,将正规接受核苷类(拉米夫定)抗乙肝病毒药物治疗的病例124例,为治疗组(A组),未接受任何抗乙肝病毒药物治疗为未治疗组(B组)496例,比较两组原发性肝癌的发生。结果3年中治疗组(A组)新发现原发性肝癌(HCC)患者4例,占3.2%;未治疗组(B组)新发现发性肝癌(HCC)患者42例,占8.5%,两者有显著差异,P<0.05。结论慢性乙肝患者长期应用拉米夫定抗乙肝病毒治疗可降低发展为原发肝癌的危险性。
Objective To investigate the effect of long-term oral lamivudine on the development of primary hepatocellular carcinoma in patients with chronic hepatitis B. Methods A retrospective analysis of 620 patients with chronic hepatitis B (CHB) diagnosed from July 2005 to July 2008 was conducted, and 124 patients who received nucleoside (lamivudine) anti-hepatitis B virus drugs formally for treatment Group A (Group A), did not receive any anti-hepatitis B drug treatment for untreated group (B group) 496 cases, compared two groups of primary liver cancer. Results Four cases (3.2%) of newly diagnosed primary hepatocellular carcinoma (HCC) were found in the treatment group (group A) in the three years; 42 cases (8.5%) of newly diagnosed hepatocellular carcinoma (HCC) There was a significant difference between the two groups, P <0.05. Conclusion Long-term use of lamivudine against chronic hepatitis B patients can reduce the risk of developing primary liver cancer.